PDGF-R inhibition induces glioblastoma cell differentiation via DUSP1/p38MAPK signalling.
Ontology highlight
ABSTRACT: Glioblastoma (GBM) is the most common and fatal primary brain tumour in adults. Considering that resistance to current therapies leads to limited response in patients, new therapeutic options are urgently needed. In recent years, differentiation therapy has been proposed as an alternative for GBM treatment, with the aim of bringing cancer cells into a post-mitotic/differentiated state, ultimately limiting tumour growth. As an integral component of cancer development and regulation of differentiation processes, kinases are potential targets of differentiation therapies. The present study describes how the screening of a panel of kinase inhibitors (KIs) identified PDGF-Rα/β inhibitor CP-673451 as a potential differentiation agent in GBM. We show that targeting PDGF-Rα/β with CP-673451 in vit
SUBMITTER: Lane R
PROVIDER: S-EPMC9076540 | biostudies-literature | 2022 May
REPOSITORIES: biostudies-literature
ACCESS DATA